Specialty pharmacy intelligence for CAHs
Orphan-drug clarity, integrated with your 340B workflow.
One clear view of the FDA orphan universe: medical-benefit priorities, every Varick-relevant product and treatment, exact-match package NDCs, and patient-share impact where the public evidence supports a directional estimate.
Varick service-line map
Where the orphan universe concentrates
Counts are active FDA designation records and are non-exclusive: one record can map to more than one service line.
340B treatment logic
The molecule alone does not answer the question.
For a critical access hospital, rural referral center, sole community hospital, or free-standing cancer hospital, the orphan exclusion turns on the treatment being furnished.
The site will apply the HRSA treatment-level interpretation.
Commercial priority
Popular medical-benefit drugs, ranked by Part B spend
Medicare 2024 Part B spend provides the ranking signal. FDA NDC Directory data adds exact-name-matched package NDCs. Open any row to see the exact FDA-designated treatments, NDCs, 340B implication, and the patient share when a directional estimate is supportable.
| Rank / drug | Varick service line | NDC | 2024 Part B spend | FDA orphan signal | % of patients in orphan treatments | Open details |
|---|
Product + treatment intelligence
Every relevant product, NDC, and designated treatment together.
There is no missing-drug gap: the first two numbers count FDA designation records, while the final number consolidates repeated designations under the same product. Records outside oncology, rheumatology, urology, and neurology are not included in this explorer.
Select a product below to expand its NDC and treatment intelligence.
Percentages are directional public-source estimates, not claims-measured utilization. “Not publicly quantified” is intentional: the FDA database establishes designation and CMS reports aggregate drug-level spend, but neither source reports product users by diagnosis.
Primary sources
Built on federal data and authority
Bring orphan-drug clarity in-house
Build the specialty pharmacy controls your CAH needs before revenue is at risk.
Use this as the orphan-drug intelligence layer beside Varick’s oncology infusion model: identify the drug, match the treatment, quantify the patient-share exposure, and document the 340B path.
Important notice
Legal and data disclaimer
Orphan Drug Intelligence is a research and decision-support resource provided solely for general informational and educational purposes. It does not constitute legal, regulatory, compliance, reimbursement, coding, tax, accounting, investment, medical, or clinical advice. Use of this website does not create an attorney-client, consultant-client, provider-patient, fiduciary, or other professional relationship.
Information is compiled from FDA, CMS, HRSA, and other public or third-party sources and may be incomplete, delayed, inaccurate, or superseded. Patient-share percentages and financial-impact figures are directional estimates—not audited claims results, forecasts, or guarantees. An NDC listing or orphan designation does not, by itself, establish FDA approval, payer coverage, reimbursement, 340B eligibility, or clinical appropriateness for any patient.
Users are solely responsible for independently verifying current law and guidance, source data, covered-entity status, indication, NDC, patient eligibility, purchasing, billing, and clinical requirements with qualified legal counsel and appropriate 340B, pharmacy, compliance, coding, reimbursement, and clinical professionals before taking action. Do not use this website as the sole basis for any operational, financial, legal, or clinical decision.
To the fullest extent permitted by applicable law, Varick and its affiliates provide this website and its content “as is,” without warranties of any kind, and disclaim responsibility or liability for losses, damages, penalties, claims, or decisions arising from use of, inability to use, or reliance on this website or any linked third-party content.
Consult qualified counsel before implementing any 340B purchasing or billing policy.